We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+28.21%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$484M
AUM Growth
-$276M
Cap. Flow
-$350M
Cap. Flow %
-72.29%
Top 10 Hldgs %
53.23%
Holding
55
New
5
Increased
9
Reduced
24
Closed
12

Top Buys

Rank Stock Value
1
PETX
Aratana Therapeutics, Inc.
PETX
+$13.8M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$7.59M
3
MYGN icon
Myriad Genetics
MYGN
+$7.31M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$5.08M
5
MTNB icon
Matinas BioPharma
MTNB
+$2.94M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$32.8M
2
DXCM icon
DexCom
DXCM
+$15.8M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.8M
4
ADMA icon
ADMA Biologics
ADMA
+$9.71M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$8.38M

Sector Composition

Rank Sector Weight
1 Healthcare 82.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYGN icon
26
Myriad Genetics
MYGN
$530M
$7.97M 1.65%
+240,000
New +$7.31M
IART icon
27
Integra LifeSciences
IART
$1.54B
$7.89M 1.63%
141,572
-55,000
-28% -$2.8M
VRAY
28
DELISTED
ViewRay, Inc.
VRAY
$6.4M 1.32%
866,500
– –
OPTN
29
DELISTED
OptiNose
OPTN
$6.03M 1.25%
39,040
-8,333
-18% -$966K
SLGL icon
30
Sol-Gel Technologies
SLGL
$268M
$5.74M 1.19%
84,770
– –
ADMA icon
31
ADMA Biologics
ADMA
$1.92B
$5.61M 1.16%
1,479,243
-2,746,834
-65% -$9.71M
HRTX icon
32
Heron Therapeutics
HRTX
$86.3M
$5.08M 1.05%
207,998
+88,704
+74% +$2.32M
VCEL icon
33
Vericel Corp
VCEL
$2.3B
$4.77M 0.99%
272,550
+82,550
+43% +$1.51M
LIVN icon
34
LivaNova
LIVN
$4.3B
$4.67M 0.96%
48,000
-3,000
-6% -$280K
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
$4.47M 0.92%
3,102,673
– –
NEOS
36
DELISTED
Neos Therapeutics, Inc
NEOS
$4.21M 0.87%
1,611,999
-1,006,820
-38% -$2.36M
MTNB icon
37
Matinas BioPharma
MTNB
$1.55M
$2.97M 0.61%
+54,545
New +$2.94M
EIGR
38
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.7M 0.56%
6,443
+1,666
+35% +$669K
TLGT
39
DELISTED
Teligent, Inc
TLGT
$2.31M 0.48%
199,098
-83,240
-29% -$1.25M
ATEC icon
40
Alphatec Holdings
ATEC
$1.27B
$1.17M 0.24%
442,966
-6,619
-1% -$12.9K
OPNT
41
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$1.12M 0.23%
+85,484
New +$1.25M
RVLP
42
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$1.11M 0.23%
307,854
-220,717
-42% -$1.62M
NVLN
43
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$897K 0.19%
729,301
-500,000
-41% -$569K
KALA icon
44
KALA BIO
KALA
$11.8M
– –
-136
Closed -$1.66M
KALV
45
DELISTED
KalVista Pharmaceuticals
KALV
– –
-143,129
Closed -$2.83M
SPY icon
46
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-700,000
Closed -$175M
TNDM icon
47
Tandem Diabetes Care
TNDM
$1.17B
– –
-89,100
Closed -$3.38M
XBI icon
48
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-700,000
Closed -$50.2M
NVRO
49
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-300,000
Closed -$11.7M
ACGN
50
DELISTED
Aceragen Inc
ACGN
– –
-28,652
Closed -$1.35M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Broadfin Capital held 55 positions worth $484M, down 36% from $761M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Broadfin Capital withdrew a net $350M in Q1 2019, closing 12 positions and reducing 24 holdings. Its most notable exit was TESARO, Inc., an estimated $32.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 56% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Myriad Genetics worth $7.97M.

  • Broadfin Capital's largest Q1 2019 buy was Myriad Genetics: 240,000 shares worth $7.97M.
  • Broadfin Capital added most to Aratana Therapeutics, Inc. in Q1 2019, an estimated $13.8M increase.
  • Broadfin Capital's biggest Q1 2019 reduction was DexCom, cutting an estimated $15.8M.
  • Broadfin Capital fully exited TESARO, Inc. in Q1 2019, selling an estimated $32.8M.
  • Broadfin Capital's ten largest holdings make up 53% of its $484M portfolio in Q1 2019.
  • Broadfin Capital opened 5 new positions and closed 12 in Q1 2019.
  • Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $484M.

Based on Broadfin Capital's 13F filing for Q1 2019, filed 15 May 2019.